Oculis Holding has reported that the randomised Phase II Acute OptiC NeUrITis of DemYelinating Origin (ACUITY) trial of OCS-05, in treating individuals with acute optic neuritis, met the primary ...

Optic Neuritis companies are Aerie Pharmaceuticals, Abbvie, Bausch Health Companies Inc., Merck, Pfizer, Teva Pharmaceutical, EyePoint Pharmaceuticals, Amorphex ...

LHON, NMO-associated optic neuritis, paraneoplastic optic neuropathy or retinopathy, autoimmune associated optic neuropathy: Treatment with TNF-antagonist (e.g., infliximab, adalimumab and etanercept) ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study published online Dec ...

If you have blurry vision, you might chalk it up to age or needing new glasses. But it can be a sign of other health problems, too. Learn more from WebMD health experts.

Source Reference: Cai CX, et al "Semaglutide and nonarteritic anterior ischemic optic neuropathy" JAMA Ophthalmol 2025; DOI: 10.1001/jamaophthalmol.2024.6555. Secondary Source JAMA Ophthalmology ...

Optical Coherence Tomography (OCT) imaging was used to objectively measure the thickness of two different retinal segments in the affected eye to evaluate the potential neuroprotective effects of ...

Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic nerve in a phase 2 study. The ACUITY trial in France analyzed 33 patients ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpo ...